Company profile

Bayer

Diversified pharma

BAYRY · XETRA · Germany

Public Market Listing

BAYRYXETRA

XETRA primary exchange listing

Live quotes, historical charts, and market capitalization for Bayer are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(16 total)

16Total Assets

7Approved

2Phase 3 / Filed

7Phase 1–2 / Early

5Diseases

Showing 16 of 16 assets

		Target & Modality
BAY2927088	Approved	HER2 (ERBB2) exon 20 insertions and point mutations; alsoSmall molecule	Non-Small Cell Lung Cancer
Finerenone(Kerendia)	Approved	Mineralocorticoid receptorSmall molecule	Heart FailureChronic Kidney Disease
Iloprost(Ventavis)	Approved	IP receptor (prostacyclin pathway)Peptide	Hypertension
Interferon beta-1b	Approved	Interferon beta receptor (type I IFN signaling) · Type I interferon receptorBiologic — subtype unspecified	Multiple Sclerosis
Larotrectinib	Approved	TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)Small molecule	Non-Small Cell Lung Cancer
Riociguat(Adempas)	Approved	Soluble guanylate cyclaseSmall molecule	Hypertension
Vericiguat(Verquvo)	Approved	Soluble guanylate cyclaseSmall molecule	Heart Failure
MolidustatNo recent activity	Phase 3	HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule	Chronic Kidney Disease
Sevabertinib	Phase 3	EGFR/HER2Small molecule	Non-Small Cell Lung Cancer
AB-1002	Phase 2	Protein inhibitor-1 (gene therapy)Gene therapy / editing	Heart Failure
BAY 3713372	Phase 2	PRMT5Small molecule	Non-Small Cell Lung Cancer
BAY3283142	Phase 2	Soluble guanylate cyclaseSmall molecule	HypertensionChronic Kidney Disease
Mosliciguat	Phase 2	Soluble guanylate cyclaseSmall molecule	Hypertension
BAY1237592No recent activity	Phase 1	Soluble guanylate cyclaseSmall molecule	Hypertension
BAY2965501	Phase 1	Diacylglycerol kinase zeta (DGKζ)Small molecule	Non-Small Cell Lung Cancer

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.